Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Barinthus Biotherapeutics (BRNS) Other Working Capital Changes (2020 - 2025)

Barinthus Biotherapeutics (BRNS) has disclosed Other Working Capital Changes for 6 consecutive years, with -$84000.0 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Other Working Capital Changes rose 97.13% year-over-year to -$84000.0, compared with a TTM value of -$132000.0 through Sep 2025, up 96.92%, and an annual FY2024 reading of -$1.8 million, up 18.68% over the prior year.
  • Other Working Capital Changes was -$84000.0 for Q3 2025 at Barinthus Biotherapeutics, up from -$294000.0 in the prior quarter.
  • Across five years, Other Working Capital Changes topped out at $5.5 million in Q3 2021 and bottomed at -$4.8 million in Q4 2021.
  • Average Other Working Capital Changes over 5 years is -$241437.5, with a median of -$189000.0 recorded in 2025.
  • The sharpest move saw Other Working Capital Changes tumbled 1014.52% in 2021, then surged 1252.71% in 2022.
  • Year by year, Other Working Capital Changes stood at -$4.8 million in 2021, then surged by 34.19% to -$3.1 million in 2022, then grew by 29.76% to -$2.2 million in 2023, then surged by 113.36% to $294000.0 in 2024, then crashed by 128.57% to -$84000.0 in 2025.
  • Business Quant data shows Other Working Capital Changes for BRNS at -$84000.0 in Q3 2025, -$294000.0 in Q2 2025, and -$48000.0 in Q1 2025.